%0 Figure %A Jiao, Shiping %A Wu, Minqing %A Ye, Feng %A Tang, Hailin %A Xie, Xinhua %A Xie, Xiaoming %D 2014 %T p-ERK1/2 as a meaningful biomarker in triple-negative breast cancer. %U https://plos.figshare.com/articles/figure/_p_ERK1_2_as_a_meaningful_biomarker_in_triple_negative_breast_cancer_/964054 %R 10.1371/journal.pone.0092172.g001 %2 https://ndownloader.figshare.com/files/1422934 %K Biochemistry %K cell biology %K Cell processes %K Cell death %K Molecular cell biology %K molecular biology %K Molecular biology techniques %K Gene therapy %K Clinical genetics %K epidemiology %K Cancer epidemiology %K Molecular epidemiology %K oncology %K Cancers and neoplasms %K Breast tumors %K breast cancer %K Cancer treatment %K pharmacology %K Drug research and development %K drug discovery %K biomarker %K triple-negative %X

A and B. Kaplan-Meier curves showed overall survival (OS) and disease-free survival (DFS) according to p-ERK1/2 expression. C. Aberrant p-ERK1/2 expression but absent expression of Bik were exhibited in the same triple-negative breast cancer patients’ samples. D. Co-overexpression of p-ERK1/2 and Bcl-Xl or Mcl-1 in the same breast cancer patients’ samples. E. The distribution of p-ERK1/2, Bik, Bcl-Xl and Mcl-1 status categorized by subgroup. F. The relative expression levels of Bik and p-ERK1/2 in eight breast cancer patients (five TNBC and three NTNBC) by western blotting. Semi-quantitative analysis for Bik and p-ERK1/2 expression: β-actin and total ERK1/2 as control respectively.

%I PLOS ONE